Research programme: Wnt pathway activators - Samumed

Drug Profile

Research programme: Wnt pathway activators - Samumed

Alternative Names: Research programme: Wnt pathway activators - Wintherix; WX 04554

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Wintherix
  • Developer Samumed
  • Class Small molecules
  • Mechanism of Action Osteogenesis stimulants; Wnt signalling pathway stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • Available For Licensing Yes

Highest Development Phases

  • No development reported Bone disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bone-disorders in USA
  • 01 Sep 2013 This programme is no longer listed as being available for licensing.
  • 01 Sep 2013 Winterix is now called Samumed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top